Transforming Potential Into Value
A U.S. business accelerator for Nordic life sciences
Nordicus Partners is the only publicly traded U.S. business accelerator and holding company focused exclusively on empowering Nordic life sciences companies to succeed in the U.S. market. By combining Nordic scientific innovation with U.S. operational expertise, Nordicus targets transformative, scalable opportunities in high-growth life sciences with unmet medical needs.
The Company advises and invests in Nordic and U.S. life sciences companies through a team of American and Nordic professionals. Its scientific foundation targets inflammation and immune modulation, starting with oral disorders where no approved medical treatment exists today.
Nordicus is headquartered in Beverly Hills, California, with a Nordic office in Søborg, Denmark, and its common stock trades on the OTCQB Market under the symbol “NORD.”
Portfolio Companies
Explore the portfolioOrocidin A/S
Developing treatments for aggressive periodontal disease.
Next milestonePhase IIa trial in patients planned H1 2027 at the University of Copenhagen
Bio-Convert A/S
Focused on preventing oral leukoplakia (OLK), a potentially cancerous lesion in the mouth.
Next milestoneGMP manufacturing by December 2026; Phase IIa in Europe H1 2027
NoviThera ApS
Developing a novel antibody therapy for psoriasis.
StatusBiological proof of concept established in preclinical study
Status as reported in the Company’s corporate update of June 15, 2026.
Our History
- 1993
Founded as CardioTech International, Inc.
- 2008
Renamed AdvanSource Biomaterials Corporation.
- 2020
Operating business acquired by Mitsubishi Chemical Performance Polymers; renamed EKIMAS Corporation.
- 2023
Reverse acquisition with Nordicus Partners A/S; renamed Nordicus Partners Corporation, ticker NORD.
- 2024
Uplisted to the OTCQB Market; acquired Orocidin A/S and Bio-Convert.
- 2025
Applied to uplist to the Nasdaq Capital Market; formed NoviThera ApS.